Epigenetic modifications, such as DNA methylation, assure the proper regulation of gene expression, controlling which part of the instructions (DNA) contained in a cell will be executed and which ones will be silenced. In cancer cells this mechanism is altered. When cells die their content is released to the bloodstream, including DNA. Measuring the methylation state of circulating DNA fragments specifically derived from cancer cells can give accurate information about the cell status and it can be used as biomarker for cancer screening and monitoring.
UDX has identified a proprietary panel of biomarkers that allows to differentiate cancer and adenoma patients from healthy individuals from a simple blood test.